43 results
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
9 May 24
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:11pm
of corporate leadership, product development, and value creation will be instrumental to guide the Company as it advances its potentially best-in-class
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
partners at Paragon. Prior to the closing of the Asset Acquisition, Paragon had sole leadership in conducting in vitro and in vivo studies for SPY001 clones … to his extensive leadership experience in the biopharmaceutical industry.
Mark McKenna. Mr. McKenna has served as a director since February 2024. Mr
POS AM
oohr365co1rrs9grn0
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
POS AM
cpzv5
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
8-K
EX-99.1
rvza z8ls5wyt
29 Feb 24
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:14pm
424B3
nxfa771p ia9
30 Nov 23
Prospectus supplement
5:18pm
8-K
EX-99.1
8y5tonnehoa2mtpjnz
28 Nov 23
Appoints CEO and Additional Directors, and Expands Leadership Team to
7:33am
8-K
EX-99.1
ef9a9p
9 Nov 23
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
8-K
EX-99.1
vy6ffi j1
24 Oct 23
Regulation FD Disclosure
9:00am
8-K
EX-99.1
gsj k6b2qy
8 Sep 23
Material Modifications to Rights of Security Holders
5:05pm